drugset / Trial / NCT06284902

Bioavailability Study of Fexofenadine HCl New Formulation Tablet

NCT06284902

Phase 1 Completed 25 enrolled Opella Healthcare Group SAS
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of the study is to assess the relative bioavailability of a new galenic form of fexofenadine HCl new formulation tablet (test drug) taken with or without water compared to fexofenadine HCl film-coated tablets (reference form) taken with water under fasting conditions.

Timeline

Start
2024-02-23
Primary completion
2024-05-08
Completion
2024-05-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Fexofenadine Unknown

Indications

No indication recorded.